34 Posts Not to Miss From ESMO24 Day 4
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.
This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.
Doctors and professionals shared their insights on social media.
“Hot off the press.
Read my comments on the ESMO – European Society for Medical Oncology Presidential Symposium Precision Oncology trials and DRUP-like trials presented at ESMO24:
Drug rediscovery trials facilitate access to Precision Oncology and highlight the importance of integrating comprehensive Genomic Profiling into clinical practice across a broad range of tumour types.”
“What a great emotion to present the the Rome trial results at ESMO 24 Presidential Session!!!!!
One of the greatest of my life!!! Precision medicine is growing, and as a friend of mine says : it’s becoming an adult Benedikt Westphalen !! thanks a lot to my great mentor Paolo Marchetti, to Giuseppe Curigliano, all Rome trial centers and to our dream team!!!!”
“An amazing ESMO-SIOG session on multidisciplinary approach to management of older adults with cancer today at ESMO24.
Had the privilege to co-chair this with Boulahssass Rabia and work with Etienne Brain, Laura Biganzoli and Axel S. Merseburger in coming up with 2 interesting cases in prostate and breast cancer highlighting importance of MDTs in personalizing care for our older adults with advanced cancer based on the latest evidence.
Looking forward to more data in this space at the SIOG – International Society of Geriatric Oncology annual meeting in Montreal next month.
Many thanks to ESMO – European Society for Medical Oncology for organising this special sesion in this years meeting.”
“An exciting experience to attend ESMO – European Society for Medical Oncology with 5000 visitors from all over the world. Barcelona delivered warm weather, and the congress a networking and learning environment.
A special thank you to my friends in the Cancer Mission Board who were there, and for the opportunity to present the ECPC a coming portal for patients for sharing data and communicate with others in the Cancer area.”
ESMO:
“Pembrolizumab added to chemotherapy should be considered a new standard of care for early-stage triple-negative Breast Cancer (TNBC), according to Carmen Criscitiello.
Commenting on the final results of the KEYNOTE-522 study that were presented in a Presidential Symposium at ESMO24, she says that the data represent some of the most significant results observed in the treatment of Early Breast Cancer.
The addition of pembrolizumab significantly prolonged OS, suggesting that it has the potential to transform management.”
“Barcelona is almost over – was nice to see the ideas and plans of our scientific sarcoma track subcommittee come to fruition. It was a good collaboration as always, led by track chair Bernd Kasper.
Also happy to give a lecture in the multidisciplinary session discussing response after neo-adjuvant treatment of soft tissue sarcoma and the impact on surgery.
Together, we, as the international sarcoma community, try to constantly improve our multidisciplinary treatment strategies since we want to do better for our patients and give them a better chance and more hope.”
“SIOPE is delighted to attend the ESMO Congress in Barcelona.
It is very important for us to be here and foster our collaboration, especially in the AYA field.”
SIOG:
“The ESMO/SIOG working group hosted a special session today at ESMO24 highlighting the holistic approach to cancer care for older adults:
‘Working together in the era of personalized care for older adults with cancer.’”
“ESMO2024 also means face-to-face interactions, discussing projects results of the MeTe and the NIRVANA studies, future ideas, and challenging with special colleagues all around the world.
Today a vibrant poster walk for NET.”
“Incredibly proud of Peter de Gooyer from my group presenting NICHE-3 on neoadjuvant nivo/rela in dMMR colon cancer at ESMO24 with concomitant publication in Nature Medicine.”
“Excellent talk by Christopher Sweeney bringing mCRPC treatment options, personalized therapies, biomarker guided treatment into context.
Personalised treatment is needed but we need to do much better! Too many failed all-comer strategies in Prostate Cancer.”
“It is not surprising anymore to see Myriam Chalabi presenting some mind blowing data and no questions these are impactful to practice.
I think it is still important to entertain some thought process and some discussion around these impressive results.”
“Barcelona always in my heart. Successful meeting at ESMO24, to connect with friends and fantastic leaders in the field Vivek Subbiah, Haeseong Park and Arndt Vogel.
From all around the world~ learned about great opportunities! Hasta luego Catalonia y nos vemos en Berlin.”
“As ESMO24 draws to a close… thanks to ESMO for bringing the global oncology community together!
To start…
We are Greece, We are Ireland, We are Georgia, We are South Africa.”
“The best of ESMO 2024.
Presidential Symposium III: Eyes to the Future!
Precision Immuno-Oncology for advanced NSCLC patients with PD-(L)1 inhibitor resistance.
PIONeeR: Phase Ib/IIa clinical trial targeting identified resistance pathways.
Groundbreaking trial to overcome ICI resistance!”
“Talk about a FUN group at ESMO24.”
“The AMBASSADOR trial confirms the benefit of adjuvant pembrolizumab with extended fu 45 months:
regardless of PD-L1 status and lower tract.”
“Agree!
Steroids are the mainstay for treating ADC-induced ILD (but cause long-term toxicity)
Inhaled steroids are much better tolerated and provide benefit in RT-induced ILD and several other conditions (asthma, COVID)
Time to study them for preventing ADC-induced ILD!”
“Leaving ESMO24 after a fantastic meeting. Thanks ESMO for the honour of being Prostate Track Chair (passing the baton to Deborah Mukherji in 2025).
And the chance to present UpFrontPSMA trial.
Many great advances for Prostate Cancer patients and happy times with friends.”
“Andrea Necchi brilliantly reported updated results of SunRISe-4 study at ESMO24. Cetrelimab and TAR200 are better than cetrelimab alone, but some issues arise from selection of patients (cT2 vs. cT3-4) and % of patients ineligible vs. refusing chemo.”
“It was such a great honor to talk about ‘Tumor-Agnostic Biomarker Driven Drug development: How and How often?’ at the special joint session of ASCO and ESMO
meeting.
Grateful to our beloved ASCO President Robin Zon, and amazing ESMO President Andres Cervantes for the invite to the talk & their vision in putting this amazing session together.“
“Just presented at the ESMO24 Presidential Symposium III by the king Andrea Botticelli, a massive Italian precision medicine effort….fantastic presentation my friend and super important data!!!”
“An impactful ESMO24 – attending keeps you current with all the latest advances and the next generation of cancer therapies. But it’s also a way to connect with like-minded colleagues and friends!”
“Lung mini-orals
Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis:
– 292 patients
– 15% reduction in RP
– no long-term steroid tox
No need for ph III, could do tomorrow.”
ESMO:
“Promising early-phase clinical trials support strategies to target emerging actionable mutations in different solid Tumors and further expand the landscape of Precision Oncology.”
“Honored to co-chair Proffered Paper bladder cancer session ESMO24 with the amazing Maria De Santis.
All star line of up speakers and presentations!
Thanks Petros Grivas for your superb leadership of GU Non-Pca track.”
“An amazing ESMO24 is wrapping with ground breaking trials & new data to add to our cancer knowledge!
Save the date ESMO25 Oct 17-21, 2025 in Berlin — Can’t wait to see what co-chairs Toni Choueiri and Myriam Chalabi have lined up for us!”
ESMO:
“We are excited to mark the first anniversary of this initiative at ESMO24.
Thanking the ESMO Ambassadors for their stellar reporting during a year in life of the Oncology Community — stay tuned.”
“ESMOYOC rocks at ESMO24 and many other events.
We are here for you and your career development as young oncologists.”
“Until next time, ESMO24 thanks for another great congress.
To Barcelona, a beautiful host city – adiós, adéu.
Going home with top 3 breast cancer messages:
- KN522—eTNBC addition of Pembro increased OS 4.9%
- DB12—T-DXd in HER2+ brain mets is v. effective
- NATALEE—adj Ribo increased 4yr iDFS 4.9%.”
“Remembering old times. Getting together at ESMO 2024 in Barcelona after a long time of having been together.”
“Busy two weeks WCLC24 ESMO24. Two presidential abstracts, EGFR session chair and three posters! A lot of work, a lot of support from mentors, friends, and colleagues.”
“The best of ESMO 2024 is here!
Presidential Symposium III: Eyes to the Future!
TNT with non-operative management for pMMR LARC
First results of the NO-CUT trial:
cCR: 26%
DRFS30: 97%, NOM: 85%
ctDNA+ predicts recurrence
Next step: Selecting the right patients for NOM!”
“ESMO24 HL: inspiring talk by Roberto Ferrara upon pattern of progression to immunotherapy. HPD is rare but letal, and lacks of biomarkers. Mechanism is unknown. A myeloid-mediated effect is a fascinating, yet reasonable hypotesis. Neu and MDSCs characterization may be the key.”
For more details on ESMO24, visit oncodaily.com
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023